Lipid Disorder Treatment Market Size, Share, Opportunities, COVID-19 Impact, And Trends By Drug Type (Lovastatin, Atorvastatin, Rosuvastatin, Others), By Distribution Channel (Offline, Online), And Geography - Forecasts From 2019 To 2024

Published:  May 2020 Report Code: KSI061611963 Pages: 115

Global lipid disorder treatment market is projected to grow at a CAGR of 4.21% to reach US$5.509 billion by 2024, from US$4.302 billion in 2018. Lipids, or lipoproteins, are the fats found circulating in the bloodstream. Lipid disorders refer to a broad spectrum of metabolic conditions that affect blood lipid levels. They are generally characterized by elevated levels of cholesterol, triglycerides, and/or lipoproteins in the blood in association with an increased risk of (or current) cardiovascular disease. There are a number of easy ways to lower your LDLs, including avoiding foods high in saturated fat, dietary cholesterol, and excess calories; exercising; maintaining a healthy weight; and stopping smoking. Statins are the most commonly prescribed treatments for lipid treatments.

Increasing adoption of unhealthy lifestyles by consumers has increased various lifestyle diseases around the globe. Increasing prevalence of high cholesterol levels along with the increasing developments in the treatment for lipid metabolism disorders will further augment the market. According to World Health Organization a third of ischemic heart disease is attributable to high cholesterol levels. Moreover smoking and drinking have also contributed to the rising prevalence of lipid disorder, which further fuel the growth of the market.    

The Lipid Disorder Treatment Market – Forecasts from 2019 to 2024” is an exhaustive study that aims to present the key market trends through various chapters focusing on different aspects of the market. The study provides a detailed market overview through the market dynamics sections which detail key market, drivers, restraints, and opportunities in the current market. The report analyzes key opportunity regional markets, and the current technology penetration through lifecycle analysis. The report also analyzes the market through comprehensive market segmentation by drug type, distribution channel, and geography.

Based on techniques, the market has been segmented as Non-invasive and Invasive. On the basis of indication, the market is segmented as genetic diseases and infectious diseases. Based on End-Users, the market has been segmented as Hospitals and Clinics and Diagnostic Labs.

Regional analysis has been provided with detailed analysis and forecast for the period 2019 to 2024. The global market has been broken down into North America, South America, Europe, Middle East and Africa, and Asia Pacific regions. The report also analyzes major countries across these regions with thorough analysis and forecast along with prevailing market trends and opportunities which each of these countries present for the manufacturers.

Major players in the lipid disorder treatment market have been covered along with their relative competitive position and strategies. The report also mentions recent deals and investments of different market players over the last year. The company profiles section details the business overview, financial performance for the past three years, key products and services being offered along with the recent developments of these important players in lipid disorder treatment market.

Lipid Disorder Treatment Market Scope:

Report Metric Details
 Market size value in 2018  US$4.302 billion
 Market size value in 2024  US$5.509 billion
 Growth Rate  CAGR of 4.21% from 2018 to 2024
 Base year  2018
 Forecast period  2019–2024
 Forecast Unit (Value)  USD Billion
 Segments covered  Drug Type, Distribution Channel, And Geography
 Regions covered  North America, South America, Europe, Middle East and Africa, Asia Pacific
 Companies covered  Pfizer, Mylan, Teva Pharmaceuticals, Sun Pharmaceuticals Industries Ltd., Merck &   Co.
 Customization scope  Free report customization with purchase

Segmentation:

  • By Drug Type
    • Lovastatin
    • Atorvastatin
    • Rosuvastatin
    • Others
  • By Distribution Channel
    • Online
    • Offline
  • By Geography
    • North America
      • USA
      • Canada
      • Mexico
    • South America
      • Brazil
      • Argentina
      • Others
    • Europe
      • UK
      • Germany
      • Italy
      • Spain
      • Others
    • Middle East and Africa (MEA)
      • Israel
      • Saudi Arabia
      • Others
    • Asia Pacific (APAC)
      • China
      • Japan
      • India
      • Australia
      • Others

Frequently Asked Questions (FAQs)

Q1. What will be the lipid disorder treatment market size by 2024?
A1. The global lipid disorder treatment market is projected to reach a total market size of US$5.509 billion by 2024.
 
Q2. What is the size of global lipid disorder treatment market?
A2. Lipid Disorder Treatment market was valued at US$4.302 billion in 2018.
 
Q3. What are the growth prospects for lipid disorder treatment market?
A3. The lipid disorder treatment market is projected to grow at a CAGR of 4.21% during the forecast period.
 
Q4. How is the global lipid disorder treatment market segmented?
A4. The global lipid disorder treatment market has been segmented by drug type, distribution channel, and geography.
 
Q5. What factors are anticipated to drive the lipid disorder treatment market growth?
A5. The increasing prevalence of high cholesterol levels along with the increasing developments in the treatment for lipid metabolism disorders will augment the lipid disorder treatment market.
1. Introduction
1.1. Market Overview
1.2. Market Definition
1.3. Scope of the study
1.4. Currency
1.5. Assumptions
1.6. Base, and Forecast Years Timeline
 
2. Research methodology
2.1. Research Design
2.2. Secondary Sources
 
3. Executive Summary
 
4. Market Dynamics
4.1. Market Segmentation
4.2. Market Drivers
4.3. Market Restraints
4.4. Market Opportunities
4.5. Porter’s Five Forces Analysis
4.5.1. Bargaining Power of Suppliers
4.5.2. Bargaining Power of Buyers
4.5.3. Threat of New Entrants
4.5.4. Threat of Substitutes
4.5.5. Competitive Rivalry in the Industry
4.6. Life Cycle Analysis - Regional Snapshot
4.7. Market Attractiveness
 
5. Lipid Disorder Treatment Market by Drug Type
5.1. Lovastatin
5.2. Atorvastatin 
5.3. Rosuvastatin
5.4. Others 
 
6. Lipid Disorder Treatment Market by Distribution Channel
6.1. Online
6.2. Offline 
 
7. Lipid Disorder Treatment Market by Geography
7.1. North America
7.1.1. USA
7.1.2. Canada
7.1.3. Mexico
7.2. South America
7.2.1. Brazil 
7.2.2. Argentina
7.2.3. Others
7.3. Europe
7.3.1. UK
7.3.2. Germany
7.3.3. Italy
7.3.4. Spain
7.3.5. Others
7.4. Middle East and Africa
7.4.1. Israel
7.4.2. Saudi Arabia
7.4.3. Others
7.5. Asia Pacific
7.5.1. China
7.5.2. Japan
7.5.3. India
7.5.4. Australia
7.5.5. Others
 
8. Competitive intelligence
8.1. Competitive Benchmarking and Analysis
8.2. Strategies of Key Players
8.3. Recent Investments and Deals 
 
9. Company Profile
9.1. Pfizer
9.2. Mylan
9.3. Teva Pharmaceuticals
9.4. Sun Pharmaceuticals Industries Ltd.
9.5. Merck & Co.

Pfizer

Mylan

Teva Pharmaceuticals

Sun Pharmaceuticals Industries Ltd.

Merck & Co.

Pricing

Explore Custom Options available with this study:

  •  Request customization
  •  Buy sections of the study
  •  Buy country specific report
  •  Request excel, Historical data
  •  Subscription inquiry
  •  Request special pricing

Our Value Proposition

Analyst Support

All our studies come with 2 months of analyst support.


Confidentiality

We are in compliance with the global privacy laws.

Connect With Us